Clinical trials: Lymphatic System Neoplasm
Multiple Myeloma
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
- Trial name
- NCT05372354
- Testing
- CC-92480, Tazemetostat, BMS-986158
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 260 people
- Sponsor
- Bristol-Myers Squibb
Leukemia, Lymphoma
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Graft Versus Host Disease
- Trial name
- NCT00003056
- Testing
- cyclosporine, cyclosporine and methotrexate
- Where
- 13 sites in United States, Australia
- Volunteers
- 105 people
- Sponsor
- Baxalta now part of Shire
Acute Lymphoblastic Leukemia, Acute Leukemias
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Leukemias, Acute Myeloid Leukemia
- Trial name
- NCT07295951
- Testing
- 14C-bleximenib, bleximenib
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate tolerability of the combination therapy of JNS002 and bortezomib in Japanese bortezomib-naive patients with multiple myeloma who have ever received at least 1 line of chemotherapy.
- Trial name
- NCT01371227
- Testing
- JNS002
- Where
- 2 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Janssen Pharmaceutical K.K.
Multiple Myeloma (MM), Cancer
A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
This first-in-human study will evaluate the safety and tolerability of ABBV-467 in adult participants with relapsed/refractory multiple myeloma (MM).
- Trial name
- NCT04178902
- Testing
- ABBV-467
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 8 people
- Sponsor
- AbbVie
Fatigue, Multiple Myeloma
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
The purpose of this study is to evaluate the efficacy of armodafinil for the treatment of cancer-related fatigue in adult patients with multiple myeloma.
- Trial name
- NCT01160380
- Testing
- armodafinil
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Oncotherapeutics
Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
This trial is a multicenter, open-label, single-arm, dose-escalation and dose-expansion clinical trial. The dose was increased according to the "3 + 3" rule.
- Trial name
- NCT07035379
- Testing
- TRS005, Cyclophosphamide, Doxorubicin
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
This study aims to evaluate the efficacy of single agent loncastuximab tesirine compared to idelalisib in participants with relapsed or refractory follicular lymphoma.
- Trial name
- LOTIS-6 (NCT04699461)
- Testing
- Loncastuximab Tesirine, Idelalisib
- Where
- 34 sites in United States, Belgium and 8 more
- Volunteers
- 6 people
- Sponsor
- ADC Therapeutics S.A.
Marginal Zone Lymphoma, MZL
Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma
This is a single arm study to evaluate the efficacy, safety and tolerability of zanubrutinib (BGB-3111) in participants with relapsed/refractory marginal zone lymphoma (R/R MZL).
- Trial name
- MAGNOLIA (NCT03846427)
- Testing
- Zanubrutinib
- Where
- 31 sites in United States, Australia and 7 more
- Volunteers
- 68 people
- Sponsor
- BeiGene
Multiple Myeloma, Refractory, Multiple Myeloma in Relapse
LMY-920 for Treatment of Relapsed or Refractory Myeloma
Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even…
- Trial name
- LMY-920-002 (NCT05546723)
- Testing
- Autologous CAR-T cell therapy expressing the BAFF-ligand.
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Luminary Therapeutics
Lymphoma
PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy
The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lymphoma receiving chemotherapy.
- Trial name
- NCT02805218
- Testing
- PEG-rhG-CSF
- Volunteers
- 410 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Follicular Lymphoma
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
A study to evaluate the safety and efficacy of duvelisib administered in combination with rituximab vs placebo in combination with rituximab in patients with previously treated CD20-positive follicular lymphoma who are not…
- Trial name
- DYNAMO + R (NCT02204982)
- Testing
- Duvelisib, Rituximab
- Where
- 5 sites in Australia, France and 2 more
- Volunteers
- 13 people
- Sponsor
- SecuraBio
Non-Hodgkin's Lymphoma
Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab
SUMMARY: This is a multi-center open label study to evaluate the safety and effectiveness of Treanda™ (also known as bendamustine HCl or SDX-105) in patients who have indolent Non-Hodgkin's lymphoma and have relapsed within a…
- Trial name
- NCT00139841
- Testing
- Bendamustine HCl
- Where
- 40 sites in United States, Canada and 1 more
- Volunteers
- 103 people
- Sponsor
- Cephalon
Cancer Pain
Real-world Study of the Effectiveness and Tolerability of Outpatient Titration of OxyContin for the Moderate and Severe Pain in Cancer Patients
The purpose of this observational study is to evaluate the effectiveness and tolerability of outpatient titration regimen with OxyContin as background for moderate and severe pain in cancer patients in adult patients with…
- Trial name
- NCT07869797
- Where
- 20 sites in China
- Volunteers
- 378 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib versus Chlorambucil)
- Trial name
- NCT01724346
- Testing
- Ibrutinib, Next-line ibrutinib
- Where
- 88 sites in United States, Australia and 14 more
- Volunteers
- 269 people
- Sponsor
- Pharmacyclics LLC.
B-cell Non Hodgkin Lymphoma, Richter's Transformation
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.
- Trial name
- NCT03778073
- Testing
- Cosibelimab, Cosibelimab + Ublituximab + Bendamustine combination
- Where
- 9 sites in United States
- Volunteers
- 18 people
- Sponsor
- TG Therapeutics, Inc.
Chronic Myeloid Leukemia
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
The purpose of this study is to compare the efficacy of ponatinib and imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.
- Trial name
- NCT01650805
- Testing
- ponatinib, imatinib (Gleevec/ Glivec)
- Where
- 170 sites in United States, Australia and 22 more
- Volunteers
- 307 people
- Sponsor
- Ariad Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
The purpose of this study was to determine the maximum tolerated dose (MTD), recommended dose for expansion (RDFE), safety and tolerability of BGB-10188 as monotherapy in participants with relapsed/refractory (R/R) mature B-cell…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT04282018
- Testing
- BGB-10188, Zanubrutinib, Tislelizumab
- Where
- 24 sites in Australia, China
- Volunteers
- 97 people
- Sponsor
- BeiGene
Lymphoma
A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma
This randomized, open-label study will compare the efficacy and safety of MabThera/Rituxan (rituximab) alone, and in combination with Roferon-A (interferon alfa-2a) in patients with follicular or other CD20+ low-grade lymphoma.
- Trial name
- NCT01609010
- Testing
- rituximab, interferon-a-2a
- Where
- 31 sites in Denmark, Norway and 1 more
- Volunteers
- 313 people
- Sponsor
- Hoffmann-La Roche
Peripheral T-cell Lymphoma, NK/T-cell Lymphoma
A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma
This trial is proposed with treatment of ATG-010 combined with chemotherapy regimens which will be chosen by investigators (ICE [ifosfamide+carboplatin+etoposide] or GEMOX [gemcitabine+oxaliplatin] or Tislelizumab), after…
- Trial name
- TOUCH (NCT04425070)
- Testing
- ICE [ifosfamide+carboplatin+etoposide], GEMOX [gemcitabine+oxaliplatin], Tislelizumab
- Where
- 13 sites in China
- Volunteers
- 56 people
- Sponsor
- Antengene Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.